dc.contributorInstituto Adolfo Lutz
dc.contributorUniversidade Estadual Paulista (UNESP)
dc.contributorUniversidade de São Paulo (USP)
dc.date.accessioned2022-05-01T08:15:13Z
dc.date.accessioned2022-12-20T03:39:53Z
dc.date.available2022-05-01T08:15:13Z
dc.date.available2022-12-20T03:39:53Z
dc.date.created2022-05-01T08:15:13Z
dc.date.issued2021-08-01
dc.identifierChemotherapy, v. 66, n. 3, p. 92-98, 2021.
dc.identifier1421-9794
dc.identifier0009-3157
dc.identifierhttp://hdl.handle.net/11449/233382
dc.identifier10.1159/000517817
dc.identifier2-s2.0-85112397154
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5413481
dc.description.abstractBackground: Uropathogenic Escherichia coli (UPEC) are frequent pathogens worldwide, impacting on the morbidity and economic costs associated with antimicrobial treatment. Objectives: We report two novel mutations associated with polymyxin-B resistance in an UPEC isolate collected in 2019. Methods: Isolate was submitted to antimicrobial susceptibility testing including broth microdilution for polymyxin B. Whole genome was sequenced and analyzed. Results: Polymyxin-B total inhibition occurred at 16 mg/L (resistant). UPEC isolate was assigned to the phylogroup D, serotype O117:H4, and Sequence Type 69. mcr genes were not detected, but two novel mutations in the pmrA/basS (A80S) and pmrB/basR (D149N) genes were identified. Conclusions: The occurrence of non-mcr polymyxin resistance in E. coli from extraintestinal infections underscores the need of a continuous surveillance of this evolving pathogen.
dc.languageeng
dc.relationChemotherapy
dc.sourceScopus
dc.subjectAntimicrobial resistance
dc.subjectEscherichia coli
dc.subjectPolymyxin B
dc.subjectUropathogenic Escherichia coli
dc.subjectWhole-genome sequencing
dc.titleTwo Novel Mutations Associated with Polymyxin-B Resistance in a Pandemic Lineage of Uropathogenic Escherichia coli of the Sequence Type 69
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución